What the studies show
No adverse effects were reported in the four-week trial, consistent with its long use as a cosmetic ingredient. Four weeks in 60 people is a weak basis for a safety claim, though a topically applied hexapeptide is a low-risk proposition.
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.Am J Clin Dermatol, 2013;14:147–15360 subjects, randomised 3:1, 4 weeks, twice-daily periorbital application.
In context
Argireline is a synthetic hexapeptide (acetyl hexapeptide-8) modelled on the end of SNAP-25, the protein botulinum toxin cuts, and sold in serums as a topical wrinkle treatment. Its human evidence is one 60-person randomised trial over four weeks, which reported reduced periorbital roughness and a 48.9% subjective anti-wrinkle rate against 0% on placebo. The same study appears three times in the 2013 literature under different titles. It is a legal cosmetic ingredient everywhere LYO covers and is not a medicine.
Argireline is cosmetic ingredient. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Argireline proven to cause safety?
What studies are behind the grade?
Is Argireline approved for this?
Other outcomes for Argireline
- CPeriorbital wrinkles and skin roughness (topical)1 RCT (n=60, 4 wk)
- CSubjective wrinkle improvement (topical)1 RCT (n=60, 4 wk)
- DComparison with botulinum toxinNone
Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →